First-in-kind Human 3-dimensional Models of Parkinson’s Disease and Progressive Multiple Sclerosis Launching to the International Space Station

First-in-kind Human 3-dimensional Models of Parkinson’s Disease and Progressive Multiple Sclerosis Launching to the International Space Station

Publication date: Dec 03, 2019

First patient-derived, induced pluripotent stem cell disease-specific organoid models in microgravity to advance understanding of neurodegenerative disease The National Stem Cell Foundation (NSCF) announced today that research teams from Aspen Neuroscience and the New York Stem Cell Foundation (NYSCF) Research Institute will send a first-in-kind study of neurodegenerative disease to the International Space Station (ISS) on the nineteenth SpaceX Commercial Resupply Services (CRS-19) mission, scheduled to launch December 4th from the Kennedy Space Center in Cape Canaveral, Florida.

The NSCF-funded collaboration between researchers at the NYSCF Research Institute and Aspen Neuroscience will perform the first study of long-term cell cultures of patient-derived induced pluripotent stem cell (iPSC) neural organoids with microglia on the ISS to study Parkinson’s disease and primary progressive multiple sclerosis in microgravity.

The development of patient-specific, 3-dimensional human organoids that incorporate microglia (the inflammatory cells of the immune system implicated in the development of Parkinson’s, MS and other neurodegenerative diseases) for observation and study in the unique research environment of microgravity has the potential to enable progress across the field for a wide variety of conditions that affect a significant portion of the global population.

-There is significant potential to advance our understanding of MS and PD as we initiate these long-term studies of patient cells in microgravity now that we have completed our preliminary tests,” said Dr. Valentina Fossati, NYSCF Senior Research Investigator.

Their commitment and dedication to advancing the frontiers of science using new tools and new approaches has been inspiring to witness, and has the potential to provide an entirely new perspective on Parkinson’s and progressive MS. ” To learn more about this unique collaboration, visit The National Stem Cell Foundation is a 501(c)3 non-profit organization that funds adult stem cell and regenerative medicine research, connects children with limited resources to clinical trials for rare diseases and underwrites the National STEM Scholar Program for middle school science teachers inspiring the next generation of STEM (science, technology, engineering and math) pioneers nationwide.

For more information, visit About The New York Stem Cell Foundation (NYSCF) Research Institute The New York Stem Cell Foundation Research Institute is an independent organization accelerating cures and better treatments for patients through stem cell research.

The NYSCF Research Institute is an acknowledged world leader in stem cell research and in developing pioneering stem cell technologies, including the NYSCF Global Stem Cell Array(R) and in enabling large-scale stem cell research for scientists around the globe.

Concepts Keywords
501c3 Http
Aspen Biotechnology
Autologous Stem technologies
Bioengineering Stem cells
Biomarker Neuroscience
Biotechnology Biology
Brain Branches of biology
Cape Canaveral Biotechnology
CEO Stem cell research
Chief Executive Officer Neurodegenerative disorders
Clinical Trials Drug therapy
Commercial Resupply Services Neurodegenerative diseases
Drug Therapy Inflammatory immune system
Earth Stem disease
Earth Orbit Stem technologies
Engineering Manufacturing benefit
Florida Remote controlled systems
Globe Biotechnology
Healthcare Important breakthroughs healthcare
Immune System
International Space Station
Multiple Sclerosis
Neurodegenerative Diseases
Neurodegenerative Disorders
Space Flight
Susan Solomon
Vice President


Type Source Name
drug DRUGBANK Tropicamide
disease MESH development
pathway REACTOME Immune System
disease MESH rare diseases
disease MESH community
drug DRUGBANK Coenzyme M
disease MESH primary progressive multiple sclerosis
drug DRUGBANK Nonoxynol-9
disease MESH neurodegenerative disease
disease MESH Multiple Sclerosis


Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *